| Literature DB >> 18706263 |
Javier Pinilla-Ibarz1, Celeste Bello.
Abstract
Over the past decade, the treatment of chronic myelogenous leukemia (CML) has gone through significant advances. Once an invariably fatal disease without stem cell transplant, it has since become one of the most manageable hematologic malignancies with good long-term outcomes. However, patients are not cured and require life-long treatment, and unfortunately, some of these patients develop resistant disease that progresses despite our best treatments. As our understanding of CML continues to grow, the repertoire of drugs available for successful treatment also increases. The following review discusses the current and future therapies for CML.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18706263 DOI: 10.1007/s11912-008-0057-0
Source DB: PubMed Journal: Curr Oncol Rep ISSN: 1523-3790 Impact factor: 5.075